StreetInsider.com News Articles

Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines

Mon, 08 Sep 2025 00:15:00 -0400

HONG KONG, Sept. 7, 2025 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a strategic investment agreement with Bloomage Biotech (stock code: 688363.SH) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited.

Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics' strategic placement at HKD 12 per share, for a total investment of approximately

Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines

Mon, 08 Sep 2025 00:15:00 -0400

Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics' strategic placement at HKD 12 per share, for a total investment of approximately

Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines

Mon, 08 Sep 2025 00:15:00 -0400

Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics' strategic placement at HKD 12 per share, for a total investment of approximately

Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines

Mon, 08 Sep 2025 00:15:00 -0400

Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics' strategic placement at HKD 12 per share, for a total investment of approximately

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

Fri, 04 Oct 2024 00:30:00 -0400

HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, announced that the Company has entered into a subscription agreement with Dr. Poon Hung Fai ("Dr. Poon"), the subscriber. Dr. Poon intends to subscribe for 17,527,696 subscription shares at a subscription price of approximately HK$3.36 per share, representing approximately 16.7% of the issued share capital of the Company as enlarged by the

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

Fri, 04 Oct 2024 00:30:00 -0400

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

Fri, 04 Oct 2024 00:30:00 -0400

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

Fri, 04 Oct 2024 00:30:00 -0400

Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology